Source comparison
Tesamorelin vs HGH Fragment 176-191
HGH Fragment 176-191 is a modified fragment of the growth hormone molecule (amino acids 176-191) that is purported to stimulate lipolysis without the full spectrum of GH effects. It has never received FDA approval, has no published Phase 3 data, and is availab
This comparison does not assign a generated winner or score.
- HGH Fragment 176-191 is a modified fragment of the growth hormone molecule (amino acids 176-191) that is purported to stimulate lipolysis without the full spectrum of GH effects. It has never received FDA approval, has no published Phase 3 data, and is available only through research suppliers and some compounding pharmacies.
- The fragment does not stimulate GH release from the pituitary. It does not raise IGF-1 levels. Its mechanism is fundamentally different from tesamorelin: rather than working through the GH axis, it is thought to interact directly with fat cell receptors. The evidence for its efficacy is limited to in vitro studies and animal models, with no controlled human trials published in peer-reviewed journals.
- From a regulatory perspective, HGH Fragment 176-191 occupies the weakest position among commonly discussed fat loss peptides: no FDA approval, no clinical trial data, and uncertain legal status.